Shuttle Pharmaceuticals Holdings, Inc. (SHPH): Nasdaq/NYSE listing notice — Shuttle Pharmaceuticals Regains Nasdaq Compliance After Late Filing, Provides Pipeline Update

Shuttle Pharmaceuticals Holdings, Inc.

Received delisting notice from Nasdaq on May 24 for failure to timely file Form 10-Q, but filed on May 25 and regained compliance.
Closed private placement of $4.3M secured convertible note and warrants for $4.0M investment.
Expects final submission to FDA for Phase II trial of Ropidoxuridine in glioblastoma by end of Q2 2023.
Awarded U.S. Patent No. 11,654,157 for cancer therapies combining halogenated thymidines and thymidine phosphorylase inhibitors with radiation.
Appointed Dr. Bette Jacobs as independent director to Board.

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Shuttle Pharmaceuticals Holdings, Inc. received a nasdaq noncompliance notice notice regarding late filing (rules 12B-25).

Exchange: nasdaq
Notice: noncompliance notice
Deficiency: late filing
Rules: 12B-25

Exact text from the filing

May 24, 2023, the Company received notice from the Nasdaq Stock Market, LLC (“Nasdaq”) that we have fallen out of compliance with the Nasdaq Listing Rules for continued listing as a result of being unable to file our Quarterly Report on Form 10-Q for the period ended March 31, 2023 (the “Form 10-Q”) within the five day extension provided by Rule 12b-25 under the Securities Exchange Act of 1934, as amended. Our Form 10-Q had not been timely filed as a result of certain accounting complexities that arose in relation to our convertible note held by Alto Opportunity Master Fund, SPC – Segregated M

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Shuttle Pharmaceuticals Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-019186

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.